Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LENTICOL-F: Gene-modified Autologous Fibroblasts in RDEB
NCT02493816Phase 1Completed
- Sponsor
- King's College London
- Start
- Sep 2015
- Primary completion
- Mar 2018
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of COL7A1 gene-modified autologous fibroblasts in Recessive Dystrophic Epidermolysis Bullosa (RDEB), sponsored by King's College London. Primary endpoint: Adverse Events at 12 months. Started Sep 2015; status: completed.
02
Drugs
COL7A1 gene-modified autologous fibroblasts
03
Conditions
Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Beyond the preview
Go deeper on NCT02493816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02493816.